前列腺癌的局灶冷冻治疗

doi:10.6040/j.issn.1671-7554.0.2018.1331

摘要/Abstract

摘要： 近年来,随着前列腺癌病理学、影像学、穿刺以及冷冻技术的进展,推动了前列腺癌局灶冷冻治疗的开展。局灶冷冻治疗范围包括标志病灶及周边部分组织。术前经多参数磁共振、穿刺活检确认标志病灶,术后定期复查前列腺特异性抗原、多参数磁共振及前列腺穿刺活检。前列腺癌局灶冷冻治疗的近期无生化复发生存率与全腺体治疗相当,并且更好地保存了控尿功能与性功能。然而,前列腺癌局灶冷冻治疗的适应证、治疗方法、疗效评估方法、随访方案及远期疗效仍有待于进一步临床研究结果。

关键词: 前列腺癌, 局灶治疗, 冷冻治疗, 标志病灶, 多参数磁共振, 前列腺癌穿刺活检

Abstract: In recent years, advances in pathology, imaging, targeted biopsy and cryoablation techniques have promoted the development of focal cryoablation in the treatment of prostate cancer. Focal cryoablation targets on the index lesion and surrounding tissues. Multiparametric MRI(mpMRI)and prostate biopsy are performed to confirm the index lesion before focal cryoablation. Prostate specific antigen(PSA), mpMRI and prostate biopsy are regularly reviewed after focal 山东大学学报 (医学版)57卷1期 -周芳坚,等.前列腺癌的局灶冷冻治疗 \=-therapy. Compared with whole gland therapy, focal cryoablation has comparable biochemical recurrence-free survival, but better preservation of urinary continence and sexual function. However, further clinical trials are needed for patient selection, operating techniques, assessment of outcome assessment, follow-up modalities and long-term efficacy.

Key words: Prostate cancer, Focal therapy, Cryoablation, Index lesion, Multiparametric MRI, Targeted biopsy

中图分类号:

R737.25

周芳坚,黄华,李永红. 前列腺癌的局灶冷冻治疗[J]. 山东大学学报 (医学版), 2019, 57(1): 6-10.

ZHOU Fangjian, HUANG Hua, LI Yonghong. Focal cryoablation for prostate cancer[J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 6-10.

参考文献

[1] Langenhuijsen JF, Broers EM, Vergunst H. Cryosurgery for prostate cancer: an update on clinical results of modern cryotechnology[J]. Eur Urol, 2009, 55(1): 76-86.
[2] Cohen JK, Miller RJ Jr, Ahmed S, et al. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy[J]. Urology, 2008, 71(3): 515-518.
[3] Babaian RJ, Donnelly B, Bahn D, et a1. Best practice statement on cryosurgery for the treatment of localized prostate cancer[J]. J Urol, 2008, 180(5): 1993-2004.
[4] Edison E, Tariq Shah T, Ahmed HU. Focal Ablation of Early Stage Prostate Cancer Candidate Selection, Treatment Guidance, and Assessment of Outcome[J]. Urol Clin North Am, 2017, 44(4): 575-585.
[5] Bahn DK, Silverman P, Lee F Sr, et al. Focal Prostate Cryoablation: Initial Results Show Cancer Control and Potency Preservation[J]. J Endourol, 2006, 20(9): 688-692.
[6] Eisenberg ML, Shinohara K. Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure[J]. Urology, 2008, 72(6): 1315-1318.
[7] 董柏君, 王艳青, 谢少伟, 等. 靶向冷冻消融治疗局限性前列腺癌的临床研究[J]. 中华泌尿外科杂志, 2016, 37(10): 754-757. DONG Bojun, WANG Yanqing, XIE Shaowei, et al. Targeted cryoablation for treating localized prostate cancer[J]. Chinese Journal of Urology, 2016, 37(10): 754-757.
[8] Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013[J]. Eur Urol, 2014, 65(1): 124-137.
[9] Ahmed HU, Akin O, Coleman JA, et al. Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer[J]. BJU Int, 2012, 109(11): 1636-1647.
[10] Cordeiro ER, Cathelineau X, Thüroff S, et al. High-intensity focused ultrasound(HIFU)for definitive treatment of prostate cancer[J]. BJU Int, 2012, 110(9): 1228-1242.
[11] Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable(stage T1c)prostate cancer[J]. JAMA, 1994, 271(5): 368-374.
[12] Nevoux P, Ouzzane A, Ahmed HU, et al. Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series[J]. BJU Int, 2012, 110(4): 517-523.
[13] Ahmed HU. The index lesion and the origin of prostate cancer[J]. N Engl J Med, 2009, 361(17): 1704-1706.
[14] Diolombi ML, Epstein JI. Metastatic potential to regional lymph nodes with Gleason score ≤7, including tertiary pattern 5, at radical prostatectomy[J]. BJU Int, 2017, 119(6): 872-878.
[15] Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy[J]. J Urol, 2011, 185(3): 869-875.
[16] Ahmed HU, Arya M, Freeman A, et al. Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?[J]. Lancet Oncol, 2012, 13(11): e509-e517.
[17] Villers A, Puech P, Mouton D, et al. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings[J]. J Urol, 2006, 176(6 Pt 1): 2432-2437.
[18] Choy B, Pearce SM, Anderson BB, et al. Prognostic significance of percentage and architectural types of contemporary Gleason pattern 4 prostate cancer in radical prostatectomy[J]. Am J Surg Pathol, 2016, 40(10): 1400-1406.
[19] Shah TT, Kasivisvanathan V, Jameson C, et al. Histological outcomes after focal high-intensity focused ultrasound and cryotherapy[J]. World J Urol, 2015, 33(7): 955-964.
[20] Valerio M, Cerantola Y, Eggener SE, et al. New and established technology in focal ablation of the prostate: a systematic review[J]. Eur Urol, 2017, 71(1): 17-34.
[21] Ritch CR, Katz AE. Update on cryotherapy for localized prostate cancer[J]. Curr Urol Rep, 2009, 10(3): 206-211.
[22] Ganzer R, Arthanareeswaran VKA, Ahmed HU, et al. Which technology to select for primary focal treatment of prostate cancer?-European Section of Urotechnology(ESUT)position statement[J]. Prostate Cancer Prostatic Dis, 2018, 21(2): 175-186.
[23] Onik G, Miessau M, Bostwick DG. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management[J]. J Clin Oncol, 2009, 27(26): 4321-4326.
[24] Nogueira L, Wang L, Fine SW, et al. Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI[J]. Urology, 2010, 75(2): 472-477.
[25] Elshafei A, Tay KJ, Kara O, et al. Associations between prostate volume and oncologic outcomes in men undergoing focal cryoablation of the prostate[J]. Clin Genitourin Cancer, 2018, 16(2): e477-e482.
[26] Valerio M, Shah TT, Shah P, et al. Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: A prospective development study[J]. Urol Oncol, 2017, 35(4):150.e1-150150.e7.
[27] Mathew MS, Oto A. MRI-guided focal therapy of prostate cancer[J]. Future Oncol, 2017, 13(6): 537-549.
[28] Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database(COLD)Registry[J]. BJU Int, 2012, 109(11): 648-1654.
[29] Li YH, Elshafei A, Agarwal G, et al. Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: initial results from the cryo on-line data registry[J]. Prostate, 2015, 75(1):1-7.
[30] Muller BG, van den Bos W, Brausi M, et al. Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project[J]. World J Urol, 2015, 33(10): 1503-1509.

相关文章 15

[1]	许振,刁统祥,臧振杰,邵丁昌,张奇,孙鼎琪,傅强. 前列腺特异性抗原同源异构体2及其衍生指标在前列腺癌诊断中的价值[J]. 山东大学学报 (医学版), 2022, 60(6): 51-56.
[2]	孙浩瑜,姜鑫,陈守臻,曲思凤,史本康. 多参数磁共振联合前列腺健康指数对PSA灰区临床有意义前列腺癌的诊断价值[J]. 山东大学学报 (医学版), 2022, 60(6): 46-50.
[3]	史本康,陈守臻,曲思凤,王勇,刘磊. 临床常见快速进展前列腺癌临床特点及研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 110-116.
[4]	徐兵,李勇,刘明,刘永辉. 沉默PRRX1基因表达可增强前列腺癌耐药细胞株PC-3/DTX对多西他赛的敏感性[J]. 山东大学学报 (医学版), 2021, 59(6): 103-110.
[5]	孙鼎琪,傅强,张辉,刘帅,刁统祥,曹庆伟,张克勤. 多参数磁共振与经直肠超声融合前列腺靶向穿刺活检在检测PI-RADS≥3前列腺癌中的临床价值[J]. 山东大学学报 (医学版), 2021, 59(4): 108-113.
[6]	吕家驹,胡佳林,丁森泰. 前列腺癌局部治疗的研究进展[J]. 山东大学学报 (医学版), 2019, 57(1): 1-5.
[7]	翟红运, 张登禄, 王光杰, 孔峰, 程广辉, 赵升田. 小鼠胚胎干细胞分泌因子对前列腺癌细胞作用的体外研究[J]. 山东大学学报（医学版）, 2015, 53(9): 8-12.
[8]	史小武, 赵苏. 喉罩通气下冷冻联合球囊扩张治疗严重良性中央气道狭窄的临床研究[J]. 山东大学学报（医学版）, 2014, 52(11): 68-72.
[9]	丁焕1，孙颖1，黎晓晴2，黎莉1. PARP抑制剂联合吉西他滨或多西他赛对雄激素非依赖性前列腺癌PC3细胞增殖的影响[J]. 山东大学学报（医学版）, 2014, 52(1): 33-36.
[10]	高逢彬，司曼飞，刘永青，牛蕾蕾，苑辉卿. 网脊衣酸上调p21CIP1蛋白诱导前列腺癌细胞周期阻滞的作用分析[J]. 山东大学学报(医学版), 2013, 51(12): 34-40.
[11]	于张健1，张士宝1，刘庆勇1，阮喜云2，杨广笑3，王全颖3. SAC重组腺相关病毒载体的构建及其对前列腺癌CAM移植瘤的抑制作用[J]. 山东大学学报(医学版), 2012, 50(7): 41-.
[12]	许爱辉1，潘喆2，蒋汉明1，孔峰1，胡志敏3，苑辉卿1. 地前素M抗前列腺肿瘤活性的初步探讨[J]. 山东大学学报(医学版), 2010, 48(5): 18-22.
[13]	陈卫国1，龙慧民2，侯建全1，浦金贤1，严春寅1. Gefitinib对激素非依赖性前列腺癌的治疗及其效应初探[J]. 山东大学学报(医学版), 2010, 48(1): 52-55.
[14]	吉恺,孔峰,沈涛,王小玲,许爱辉,苑辉卿,张秀田 . 没药倍半萜成分的分离鉴定及抗肿瘤活性[J]. 山东大学学报(医学版), 2008, 46(4): 344-348.
[15]	王小玲,孔峰,许爱辉,吉恺,蔡捷,任凯,苑辉卿 . 没药倍半萜抑制前列腺癌细胞的增殖活性初探[J]. 山东大学学报(医学版), 2007, 45(12): 1189-1192.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed